Circulating Tumor Cell Clinical Research

RareCyte® enables practical deployment of CTC-based liquid biopsy with instrumentation and consumables that provide an exquisitely sensitive, accurate, reproducible, and transparent workflow from blood collection to single-cell isolation.

  • Unbiased, reproducible, highly sensitive, and specific CTC detection
  • Scalable, high-capacity platform with workflow breakpoints, including slide banking, that enable multi-site execution
  • Deploy through our global contract research organization (CRO) network or in your own lab
  • Utilize cancer-specific panels or Developer panels for CTC biomarker analysis
  • Custom assay and companion diagnostics co-development through our Pharma Programs 

RareCyte panels for liquid biopsy analysis include markers used for CTC identification and for biomarker exploration. CTCs are identified as nucleated cells that express CK / EpCAM but not CD45. The Breast panel includes HER2 and ER, while the Prostate panel includes AR and ARv7, and the Checkpoint panel includes PDL1 and IRF1. The Developer panel enables you to customize your panel with up to two of your own biomarkers.
CyteFinder® HT with 80-slide capacity for clinical research.
Three-day blood stability and option to bank slides before staining enables practical multi-site workflow for clinical research.
Five-cell CTC cluster expressing drug target from a clinical research study participant. Cytokeratin (red) / EpCAM (magenta) / Drug target (green) / CD45 (yellow) / nuclei (blue)
Bank AccuCyte slides in freezer prior to staining.

Contact us to learn more about the latest applications utilizing products and workflow solutions from RareCyte →